Recently, a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference was held in Miami, Florida, USA, to address potassium homeostasis and management of dyskalemia in kidney disease . The conference was attended by a multidisciplinary group of nephrologists, endocrinologists, cardiologists, emergency medicine specialists, renal physiologists, and dietitians and consisted of an in-depth discussion on potassium homeostasis; potassium intake and outcomes in health and disease; and management of hypokalemia, acute hyperkalemia, and chronic hyperkalemia. The following manuscript represents our findings and consensus suggestions based on a review of the current literature and conference discussions of acute hyperkalemia, with the goal of facilitating knowledge translation of the key conclusions for health care professionals who work in emergency departments (EDs) and in the acute care settings.
Hyperkalemia refers to an elevation in potassium concentration, although a universal definition does not exist. Commonly, hyperkalemia is defined as a potassium concentration ≥5.5 mmol/l , but this cutoff varies depending on the individual laboratories and differs between plasma and serum measurements [3–5]. There is not a common and standardized definition for grading of the severity of hyperkalemia as mild, moderate, or severe; potassium concentrations vary depending on whether serum or plasma potassium was analyzed, with serum potassium concentrations usually being higher than plasma concentrations [3–5]. Of note, pseudohyperkalemia is a falsely elevated serum potassium concentration, which can occur due to mechanical trauma, prolonged tourniquet use (>1 minute) or fist clenching during the process of blood drawing, and through blood clotting, centrifugation, elevated white blood cell count, or thrombocytosis (Table 1) [6–9]. For the purpose of this review, acute hyperkalemia is defined as a potassium concentration above the upper limit of normal, not known to be chronic. The severity of hyperkalemia can be classified as suggested recently (Fig. 1).
The prevalence of hyperkalemia in the overall population, defined as a potassium concentration of ≥5 mmol/l; has been described to be 1.5%  and as high as 5.6% in patients who were recently started on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers . Among patients with heart failure, New York Heart Association class III and IV, with left ventricular ejection fraction <35%, who were newly started on spironolactone, the point prevalence of hyperkalemia (defined as a potassium concentration ≥5.5 mmol/l) was 19% compared to 5.6% in patients assigned to placebo . Prevalence of hyperkalemia was 8.8% in a Swiss ED (defined as serum potassium >4.7 mmol/l) and 3.6% (defined as serum potassium >5 mmol/l) in a USA ED [13,14]. When hyperkalemia was defined as serum or plasma potassium concentrations ≥6 mmol/l, the prevalence was 0.3% of patients in the ED of a Swiss university hospital . To our knowledge, there is no study of the prevalence of hyperkalemia in unselected patients presenting with acute kidney injury (AKI), but in patients in the ICU, the prevalence was 3.4% with no AKI, 8.8% in AKI stage 1, 17% in AKI stage 2, and 32.2% in AKI stage 3 . In patients with chronic kidney disease with an estimated glomerular filtration rate <30 ml/min/1.73 m2 the prevalence of hyperkalemia was 1.8% in a large USA cohort  and 4–5% in an Italian cohort .
Etiology and risk factors
Usually, hyperkalemia develops because of increased intake, decreased excretion, or because of a shift of potassium from the intracellular to the extracellular compartment. Increased intake alone is unlikely to cause hyperkalemia because of the excess capacity of the healthy kidney to excrete potassium .
Overall, major risk factors for development of hyperkalemia are worsening of kidney function as expressed by a lower estimated glomerular filtration rate, a higher baseline potassium concentration, or the presence of comorbidities, including diabetes mellitus, heart failure, and coronary artery disease [20,21]. An important additional risk factor of relevance in the ED setting is underlying rhabdomyolysis, as seen, for example, in major soft tissue trauma . Additionally, hyperkalemia has been described in patients with electrical burns and in combat victims [23,24]. Low hemoglobin concentrations and strenuous exercise are also associated with elevated potassium concentrations [25,26].
A multitude of drugs has been described to have the potential to induce hyperkalemia or be associated with it. The most commonly prescribed and important drugs in relation to hyperkalemia are potassium-sparing diuretics, mineralocorticoid antagonists (e.g., spironolactone and eplerenone), angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, direct renin antagonists, β-blockers, nonsteroidal anti-inflammatory drugs, heparin, and penicillin G [2,11,21,25,27,28]. In the ED setting, the use of succinylcholine for muscle relaxation may lead to significant hyperkalemia [29,30]. Patients taking digitalis are also at risk for hyperkalemia [31,32]. Potassium supplements and potassium-based salt substitutes may also be a cause of hyperkalemia, especially in patients with underlying chronic kidney disease or in those with simultaneous use of hyperkalemia-inducing drugs.
Several natural products and alternative medical substances have been described as associated with acute hyperkalemia and may be of relevance in patients with otherwise unclear etiology of the elevated potassium concentration. An overview of the multiple potential causes and risk factors for development of hyperkalemia is provided in Table 1.
Symptoms and consequences of hyperkalemia
While many patients are asymptomatic, hyperkalemia may manifest clinically by muscle weakness. Paresthesias and muscular fasciculations in the arms and legs might be earlier signs of hyperkalemia . Paralysis, cardiac conduction abnormalities, and cardiac arrhythmias can be lethal.
Usually, the muscle weakness associated with hyperkalemia is ascending, starting at the legs and progressing to the trunk, sometimes resembling Guillain–Barré syndrome [34–36].
The cardiac manifestations of hyperkalemia are caused by its depolarizing effects on the heart muscle cells and are usually progressive . Though a recent review suggested that the presence and nature of ECG changes together with the absolute concentration of potassium may be used as a prognosticator of outcome , it should be noted that there is a scarcity of high-quality studies on the ECG manifestations of hyperkalemia as most data stem from case reports or small case series.
One of the newer and largest studies on ECG changes in patients with hyperkalemia, including a total of 90 patients, reported that ECG is insensitive for the detection of hyperkalemia and found no correlation between the presence of T-wave changes and the serum potassium concentration . Tall, peaked T waves can, however, be early ECG signs of hyperkalemia . Decreased amplitudes of the P waves, prolonged PR interval, and widening of the QRS complex are also sometimes observed, caused by a diminished sodium influx into the cardiac myocytes [37,39]. The classic ECG pattern of hyperkalemia, which occurs with more severe QRS broadening and fusion of the QRS complex with broadened ST-T segments, is the sine wave pattern [37,39]. The electrocardiographic changes associated with hyperkalemia are known to resemble acute ST-elevation infarction or Brugada Syndrome in some cases [40–42]. However, and importantly, up to half of the patients with hyperkalemia have a normal ECG, including some patients with extreme hyperkalemia . In a retrospective study of 188 patients, the ECG abnormalities associated with adverse outcomes were QRS prolongation, symptomatic bradycardia, and junctional rhythms . Figure 2 provides examples of typical ECG changes associated with hyperkalemia.
Recognizing the lack of sensitivity of the conventional ECG for the diagnosis of hyperkalemia is important in clinical practice (see Rossignol for further review) . However, recently, computerized-analysis algorithms have been shown to be able to diagnose hyperkalemia from the ECG and may in future have a role in rapid diagnosis, especially in patients with chronic kidney disease, heart failure, or patients otherwise at risk for development of this serious electrolyte disorder [46,47].
Diagnosis of hyperkalemia in the ED
In many cases, hyperkalemia in the ED will be identified incidentally by laboratory measurement of electrolytes or venous or arterial blood gas analysis. In patients without risk factors for hyperkalemia, or when the finding of hyperkalemia is not plausible, pseudohyperkalemia (see Fig. 1) should be considered.
Point-of-care testing of whole blood potassium concentrations was evaluated in large studies and compared with central laboratory measurements: potassium measurement by point-of-care testing resulted in sufficiently accurate results with mean differences between 0.1 and 0.5 mmol/l compared with central laboratory measurement [49,50]. However, point-of-care devices that analyze whole blood cannot identify hemolysis, which may result in spurious hyperkalemia. Use of point-of-care testing should be considered in patients in whom hyperkalemia is clinically suspected based on symptoms or ECG, and in those at high risk for hyperkalemia (e.g., patients who receive dialysis treatment). The rapid availability of results may permit more rapid initiation of treatment. However, we recommend confirmation of hyperkalemia by either central laboratory measurement or another analysis by point-of-care testing, in patients with an initial finding of hyperkalemia.
An ECG is recommended to assess the presence of hyperkalemia-induced ECG changes.
In addition, further steps to clarify the etiology of hyperkalemia should be undertaken. These can include a careful evaluation of the patient’s history and medications, screening for hemolysis, assessment of kidney function, and, if applicable, investigation of the cause of AKI.
Management of acute hyperkalemia in the ED
High-quality studies on the management of acute hyperkalemia are lacking. Therefore, no international guideline exists specifically dealing with the management of hyperkalemia to date. Despite this, in 2014, the UK Renal Association published a clinical practice guideline on the treatment of acute hyperkalemia in adults, among others supported by the College of Emergency Medicine . In 2015, the Investigator Network Initiative Cardiovascular and Renal Clinical Trialists, an international organization of academic cardiovascular and renal clinical trialists dedicated to improving outcomes among patients with chronic renal or cardiac disease, convened a meeting of nephrology, cardiology, and emergency medicine international experts, to identify gaps in knowledge, set priorities for future research, and develop an algorithm for emergency hyperkalemia management reflecting expert opinion in the context of current evidence . The 2018 KDIGO conference extended this work.
Physical examination and history taking
In all patients suspected of having hyperkalemia, assessment by a physician or experienced health care provider should be performed as quickly as possible due to the potentially fatal consequences of high potassium concentrations . Rapid determination of potassium concentrations should be performed, preferably by point-of-care testing, followed by central laboratory confirmation. Medical history along with history of previous medical conditions may help to assess the cause of hyperkalemia. Table 2 provides an overview of ‘red flags’ in the assessment of causes of and risk factors for hyperkalemia, which should trigger a high index of suspicion for the potential presence of hyperkalemia .
Continuous ECG monitoring, interval blood pressure monitoring at a frequency appropriate to the clinical context, and measurement of oxygen saturation should be established in patients with hyperkalemia.
The KDIGO potassium Controversies Conference recommended cardiac monitoring and 12-lead ECG for potassium concentrations >6.0 mmol/l. The fact that severe hyperkalemia may not necessarily be associated with ECG changes [38,45,52–54] and that hyperkalemia can lead to ‘atypical’ ECG changes under certain circumstances must always be kept in mind . Therefore, one should put all hyperkalemic patients on continuous monitoring even if no typical ECG changes appear initially.
Treatment of hyperkalemia
Cellular membrane stabilization
Intravenous calcium salts should be administered immediately in hyperkalemic patients presenting with ECG changes suggesting hyperkalemia [2,51]. While some authorities prefer the use of calcium gluconate over calcium chloride because of lower tissue toxicity, others prefer calcium chloride because of a theoretical higher bioavailability . It is crucial to note that the concentration of calcium is approximately three times higher in calcium chloride than in calcium gluconate (6.8 mmol Ca2+ per 10 ml of 10% calcium chloride vs. 2.3 mmol Ca2+ per 10 ml/10% calcium gluconate) . Thus, to administer the same amount of calcium to the patient one has to use 30 ml of 10% calcium gluconate compared with 10 ml of 10% calcium chloride. The European Resuscitation Council recommends use of 10 ml 10% calcium chloride over 2–5 minutes in hyperkalemic patients with ECG changes . Calcium prevents ventricular fibrillation/tachycardia by stabilizing the cardiac cell membrane and is effective within 1–3 minutes after administration . Another dose can be administered within 5–10 minutes if no effect is seen, and repeated doses may be necessary if cardiac abnormalities resolve then recur.
If the potassium concentration is known but an ECG or placement on a monitor is not immediately possible, we suggest giving calcium to all patients with potassium concentration above 6.5 mmol/l (Fig. 3).
Caution must be observed in patients with potential digoxin toxicity since hypercalcemia may increase toxic effects of the drug . More recent data from human studies have not demonstrated worsened outcomes [58,59]. Levine et al.  reviewed 159 cases of digoxin toxicity, of which 23 received calcium. No life-threatening dysrhythmias occurred within 1 hour of calcium administration, and mortality was similar between those that received calcium (22%) and those who did not (22%). It is critical to consider that administration of calcium salts does not lower potassium concentration and that its duration of action is limited to 30–60 minutes .
Potassium shift to the intracellular compartment
Since administration of calcium salts does not result in a lowering of potassium concentrations, other measures have to be taken to shift potassium from the extracellular to the intracellular compartment, including use of insulin and β-adrenergic agonists. In a systematic review by Harel and Kamel , the optimal dose and method of intravenous short-acting insulin to lower potassium in hyperkalemia was investigated and the authors concluded that the administration of 10 units of insulin resulted in comparable lowering of potassium as the administration of 20 units, while use of the larger dose was associated with a higher risk for hypoglycemia. Glucose, 25–50 g, should be administered to the hyperkalemic patient intravenously along with the insulin . Studies from an ED in the USA compared a low insulin regimen (5 units) with a standard regimen of 10 units and showed no difference in the decrease in potassium between groups, while hypoglycemia was less common in those receiving the low insulin regimen with 5 units of insulin [61,62]. Because of the risk of hypoglycemia, blood glucose concentrations should be closely monitored. With glucose concentrations greater than 200 mg/dl (11.1 mmol/l), insulin may be given without additional glucose.
The administration of β-adrenergic agonists has been suggested as an alternative or an addition to insulin and glucose . A Cochrane review from 2015 concluded that the intravenous and nebulized administration of salbutamol were both effective. Head-to-head comparisons are few, but what data are available suggest similar effects in lowering potassium to those seen with insulin. Use of 10 mg salbutamol via nebulizer results in a significant reduction of potassium at a peak of 120 minutes after application (90 minutes for 20 mg) . The effects of salbutamol and insulin are potentially additive  and are currently under investigation (NCT04012138). This is a large dose compared with other uses of salbutamol (typically 4 × 2.5 mg wet nebulizations); as with insulin-glucose, patients should be monitored for adverse effects.
Sodium bicarbonate activates the Na+-K+-pump and corrects an underlying metabolic acidemia, potentially resulting in a lowering of serum potassium values , but data on its effectiveness are conflicting . We suggest using sodium bicarbonate only in patients with metabolic acidemia who are expected to tolerate the sodium load involved. There are few data to help choose between hypertonic and isotonic bicarbonate. We suggest taking into account the clinical context, including the patient’s sodium concentration and need for volume resuscitation.
Potassium-binding agents, dialysis and loop diuretics, are the only means to remove potassium from the body .
Loop diuretics are commonly used in management of acute hyperkalemia; however, to date, there are no studies investigating their efficacy in eliminating potassium in this setting. Loop diuretics are likely useful in hyperkalemic patients with volume overload, such as in heart failure, and potentially useful after fluid resuscitation in other patients.
There are very limited data on the use of potassium-binding agents for the management of acute hyperkalemia . While sodium polystyrene sulfonate has been in use for 60 years, its efficacy has not been studied in large randomized controlled trials. Furthermore, rare but increased adverse GI effects associated with sodium polystyrene sulfonate have been reported in two recent observational studies [68,69]. It should not be given with sorbitol because of an association between this combination and intestinal necrosis. Novel potassium binders such as patiromer and sodium zirconium cyclosilicate have recently been approved with promising results in eliminating potassium [70,71], and sodium zirconium cyclosilicate appears to have an appropriately rapid onset of action [72–75]. There is also a completed study that compared the efficacy of sodium zirconium cyclosilicate versus placebo when added to insulin and glucose in an ED setting but data are not yet available (NCT03337477). Although the onset of action for patiromer is slower, a recent small trial investigated its use in ED patients with hyperkalemia, and it was found that patiromer resulted in significantly lower serum potassium concentrations after 2 hours with no difference in adverse events . As there are no long-term studies with these novel binders, it remains unknown whether they are associated with significant gastrointestinal adverse effects.
Dialysis eliminates potassium from the blood in patients with hyperkalemia. We recommend nephrology consultation in all patients presenting to the ED with hyperkalemia and receiving dialysis therapy. Additionally, patients with therapy-refractory hyperkalemia or hyperkalemia with AKI should be referred to nephrology for consideration of dialysis.
Frequent assessment of potassium concentrations is indicated in patients with acute hyperkalemia. Because the onset of action of potassium-shifting agents insulin-glucose and β-adrenergic agonists is 30–60 minutes, a reevaluation of potassium can be performed at 60 minutes after administration [63,77,78]. Since these medications do not excrete potassium but only shift it to inside the cell, a recurrence of hyperkalemia is expected and therefore reevaluation is crucial. Rebound towards higher values may occur at 2–3 hours if potassium has not been eliminated from the body during that period . Additionally, blood glucose should be checked in patients receiving insulin-glucose because of the risk of hypoglycemia . The duration of frequent monitoring of potassium concentration, continuous cardiac monitoring, and frequent blood pressure monitoring will depend upon the severity of the hyperkalemia, the severity of its manifestations, the likelihood of rebound, and the patient’s overall clinical context and response to treatment.
Figure 3 provides an algorithm for the management of acute hyperkalemia in the ED.
In all patients presenting with acute hyperkalemia to the ED, a critical review of current medications should be performed for drugs that could cause hyperkalemia. Temporarily discontinuing inhibitors of the renin-angiotensin-aldosterone system should be considered, and a search for and treatment of any underlying condition leading to hyperkalemia should be performed. If the risk of hyperkalemia remains an ongoing issue, dietary instructions regarding low-potassium foods and avoidance of potassium-rich foods should be given to patients with moderate and severe kidney disease. Timing of further monitoring of potassium concentration, and whether as an in-patient or as an out-patient will depend upon the severity of the hyperkalemia, the severity of its manifestations, the likelihood of rebound, and the patient’s overall clinical context and response to treatment. A recent retrospective study performed at a large academic ED found that mortality of patients with hyperkalemia was dramatically lower in the group whose potassium concentration was normalized (<5.5 mmol/l) during the ED stay compared to those whose potassium concentration remained elevated . These data indicate that treatment in the ED or intensive/intermediate care units of patients with acute hyperkalemia until normalization of potassium concentrations might be preferable.
Areas of future research
As noted above, there is a lack of high-quality studies on the diagnosis and management of acute hyperkalemia. The sensitivity and specificity of various ECG changes for hyperkalemia, and for adverse outcomes, have not been systematically described. The optimal agent to shift or lower potassium concentrations is not known. The role of loop diuretics has not been evaluated in the management of acute hyperkalemia; specifically, there are no studies evaluating their potassium-lowering effect, onset of action, and the absolute amount of potassium excretion that is achievable; and their safety in patients who have recently undergone volume resuscitation is unknown. The role of new potassium-binding agents in the management of acute hyperkalemia is not well established, and larger studies are needed to understand possible rare adverse events.
In summary, acute hyperkalemia is a frequently observed problem in EDs and one with potentially fatal consequences. Monitoring of vital signs and performing a 12-lead ECG is recommended in all patients with potassium concentration >6 mmol/l. In all patients with hyperkalemia and presence of ECG changes, calcium salts should be promptly given. Additionally, measures to shift potassium to the intracellular compartment (i.e., insulin-glucose, β-adrenergic agonists) and remove it from the body should be taken. Frequent reevaluation of serum potassium concentrations is essential in order to monitor treatment success and screen for a rebound rise in serum potassium.
G.L., E.A.B., C.M.C., B.H., C.A.H., J.M., M.N., R.P.-F., Z.R., P.R., and A.J.S. participated in the KDIGO meeting (with C.M.C and R.P.-F as conference co-chairs) and reviewed the manuscript draft. G.L. led the conception for this review and provided the draft together with A.J.S. The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Relypsa, and Vifor Fresenius Medical Care Renal Pharma.
Conflicts of interest
G.L. received consultant fees and honoraria from Bayer, Fresenius Kabi, and Otsuka; travel grants from GlaxoSmithKline, Otsuka, and Pierre Fabre. C.M.C. has received consultation, advisory board membership, or research funding from Amgen, Astellas, Baxter, Boehringer Ingelheim, Janssen, Johnson & Johnson, LEO Pharma, Pfizer, and Ministry of Health Ontario; and speaker honoraria from Sanofi. C.A.H. received consultant fees from AbbVie, Amgen, AstraZeneca, Corvidia, FibroGen, Janssen, Pfizer, Relypsa, Sanifit, and University of Oxford; received research grants from Amgen, Relypsa, University of British Columbia, and Zoll; honoraria from UpToDate and is a stock-holder of Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson & Johnson, and Merck. R.P.-F. received consultant fees and speaker honorarium from Akebia, AstraZeneca, Fresenius Medical Care, Novo Nordisk; speaker honoraria from AstraZeneca and Novo Nordisk; and research support from Fresenius Medical Care. Z.R. has received grants and consulting fees from Relypsa and ZS Pharma. P.R. has received consultant fees from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, G3P, Grunenthal, Idorsia, Novartis, Novo Nordisk, Relypsa, Servier, Stealth Peptides, Vifor Fresenius Medical Care Renal Pharma. He is also a co-founder of CardioRenal. A.J.S. has received research grants and consulting fees from AstraZeneca, Bristol-Myers Squibb, Janssen, Pfizer, Portola, and Relypsa. There are no conflicts of interest for the remaining authors.
1. Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al.; Conference Participants. Potassium
homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020; 97:42–61
2. Truhlář A, Deakin CD, Soar J, Khalifa GE, Alfonzo A, Bierens JJ, et al.; Cardiac arrest in special circumstances section Collaborators. European resuscitation council guidelines for resuscitation 2015: section 4. Cardiac arrest in special circumstances. Resuscitation. 2015; 95:148–201
4. Hartland AJ, Neary RH. Serum potassium
is unreliable as an estimate of in vivo
. Clin Chem. 1999; 45:1091–1092
5. Cooper LB, Savarese G, Carrero JJ, Szabo B, Jernberg T, Jonsson Å, et al. Clinical and research implications of serum versus plasma potassium
measurements. Eur J Heart Fail. 2019; 21:536–537
6. Alhaj Moustafa M, Malkovska V, Elmahdy S, Catlett J. A challenging case of pseudohyperkalemia in chronic lymphocytic leukemia. J Investig Med High Impact Case Rep. 2017; 5:2324709617746194
7. Šálek T. Pseudohyperkalemia - potassium
released from cells due to clotting and centrifugation - a case report. Biochem Med (Zagreb). 2018; 28:011002
8. Seimiya M, Yoshida T, Sawabe Y, Sogawa K, Umemura H, Matsushita K, Nomura F. Reducing the incidence of pseudohyperkalemia by avoiding making a fist during phlebotomy: a quality improvement report. Am J Kidney Dis. 2010; 56:686–692
9. Wiederkehr MR, Moe OW. Factitious hyperkalemia
. Am J Kidney Dis. 2000; 36:1049–1053
10. Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia
in the united states. Curr Med Res Opin. 2018; 34:971–978
11. Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia
after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017; 6:e005428
12. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, et al.; Randomized Aldactone Evaluation Study (RALES) Investigators. Incidence, predictors, and outcomes related to hypo- and hyperkalemia
in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail. 2014; 7:573–579
13. Singer AJ, Thode HC Jr, Peacock WF. A retrospective study of emergency
disturbances: severity, treatment, and outcomes. Clin Exp Emerg Med. 2017; 4:73–79
14. Arampatzis S, Funk GC, Leichtle AB, Fiedler GM, Schwarz C, Zimmermann H, et al. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency
department: a cross-sectional analysis. BMC Med. 2013; 11:83
15. Pfortmüller CA, Leichtle AB, Fiedler GM, Exadaktylos AK, Lindner G. Hyperkalemia
in the emergency
department: etiology, symptoms and outcome of a life threatening electrolyte disorder. Eur J Intern Med. 2013; 24:e59–e60
16. Libório AB, Leite TT, Neves FM, Teles F, Bezerra CT. AKI complications in critically ill patients: association with mortality rates and RRT. Clin J Am Soc Nephrol. 2015; 10:21–28
17. Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium
and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016; 11:90–100
18. Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, et al. Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med. 2018; 7:E499
19. van Ypersele de Strihou C. Potassium
homeostasis in renal failure. Kidney Int. 1977; 11:491–504
20. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia
and death in patients with cardiac and renal disease. Am J Cardiol. 2012; 109:1510–1513
21. Turgutalp K, Bardak S, Helvaci I, İşgüzar G, Payas E, Demir S, Kiykim A. Community-acquired hyperkalemia
in elderly patients: risk factors and clinical outcomes. Ren Fail. 2016; 38:1405–1412
22. Rosenberry C, Stone F, Kalbfleisch K. Rhabdomyolysis-induced severe hyperkalemia
. West J Emerg Med. 2009; 10:302
23. Stewart IJ, Snow BD, Clemens MS, Sosnov JA, Ross JD, Howard JT, Chung KK. Hyperkalemia
in combat casualties: implications for delayed evacuation. Mil Med. 2017; 182:e2046–e2051
24. Navarrete N. Hyperkalemia
in electrical burns: a retrospective study in colombia. Burns. 2018; 44:941–946
25. Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, et al. Incident hyperkalemia
, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018; 24:313–320
26. Wasserman K, Stringer WW, Casaburi R, Zhang YY. Mechanism of the exercise hyperkalemia
: an alternate hypothesis. J Appl Physiol (1985). 1997; 83:631–643
27. Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia
in hospitalized patients. Am J Med Sci. 2014; 347:93–100
28. Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, et al.; TIME-CHF Investigators. Frequency and predictors of hyperkalemia
in patients ≥60 years of age with heart failure undergoing intense medical therapy. Am J Cardiol. 2012; 109:693–698
29. Levine M, Brown DF. Succinylcholine-induced hyperkalemia
in a patient with multiple sclerosis. J Emerg Med. 2012; 43:279–282
30. Cecchini J, Colchen-Personne A, Mellot F, Fischler M. Cardiac arrest and succinylcholine-induced hyperkalemia
in a patient with a triton tumor. A A Case Rep. 2014; 3:76–77
31. Bismuth C, Gaultier M, Bonnet M, Pollet J. Hyperkalemia
in massive digitalis poisoning. Biomedicine. 1973; 19:152–155
32. Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia
in a patient with unrecognized digitalis toxicity. J Toxicol Clin Toxicol. 2003; 41:373–376
33. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia
. Cleve Clin J Med. 2017; 84:934–942
34. Mansella G, Stephan FP, Bingisser R, Nickel CH. Hyperkalemia
-induced leg paresis in primary adrenal insufficiency. Clin Pract Cases Emerg Med. 2017; 1:430–432
35. Braun CT, Srivastava DS, Engelhardt BM, Lindner G, Exadaktylos AK. Lazy lips: hyperkalemia
tetraparesis-a case report from an urban emergency
department. Case Rep Emerg Med. 2014; 2014:160396
36. Kimmons LA, Usery JB. Acute
ascending muscle weakness secondary to medication-induced hyperkalemia
. Case Rep Med. 2014; 2014:789529
37. Littmann L, Gibbs MA. Electrocardiographic manifestations of severe hyperkalemia
. J Electrocardiol. 2018; 51:814–817
38. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia
. Clin J Am Soc Nephrol. 2008; 3:324–330
39. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia
. Am J Emerg Med. 2000; 18:721–729
40. Dendramis G, Petrina SM, Baranchuk A. Not all ST-segment elevations are myocardial infarction: hyperkalemia
and brugada phenocopy. Am J Emerg Med. 2017; 35:662.e1–662.e2
41. Pastor JA, Castellanos A, Moleiro F, Myerburg RJ. Patterns of acute
inferior wall myocardial infarction caused by hyperkalemia
. J Electrocardiol. 2001; 34:53–58
42. Peerbhai S, Masha L, DaSilva-DeAbreu A, Dhoble A. Hyperkalemia
masked by pseudo-stemi infarct pattern and cardiac arrest. Int J Emerg Med. 2017; 10:3
43. Peacock WF, Rafique Z, Clark CL, Singer AJ, Turner S, Miller J, et al.; REVEAL-ED Study Investigators. Real world evidence for treatment of hyperkalemia
in the emergency
department (REVEAL-ED): a multicenter, prospective, observational study. J Emerg Med. 2018; 55:741–750
44. Durfey N, Lehnhof B, Bergeson A, Durfey SNM, Leytin V, McAteer K, et al. Severe hyperkalemia
: can the electrocardiogram risk stratify for short-term adverse events? West J Emerg Med. 2017; 18:963–971
45. Rossignol P, Legrand M, Kosiborod M, Hollenberg SM, Peacock WF, Emmett M, et al. Emergency
management of severe hyperkalemia
: guideline for best practice and opportunities for the future. Pharmacol Res. 2016; 113:585–591
46. Dillon JJ, DeSimone CV, Sapir Y, Somers VK, Dugan JL, Bruce CJ, et al. Noninvasive potassium
determination using a mathematically processed ECG: proof of concept for a novel “blood-less, blood test”. J Electrocardiol. 2015; 48:12–18
47. Velagapudi V, O’Horo JC, Vellanki A, Baker SP, Pidikiti R, Stoff JS, Tighe DA. Computer-assisted image processing 12 lead ECG model to diagnose hyperkalemia
. J Electrocardiol. 2017; 50:131–138
48. Di Lullo L, Ronco C, Granata A. Chronic hyperkalemia
in cardiorenal patients: risk factors, diagnosis, and new treatment options. Cardiorenal Med. 2019; 9:8–21
49. Bloom BM, Connor H, Benton S, Harris T. A comparison of measurements of sodium, potassium
, haemoglobin and creatinine between an emergency
department-based point-of-care machine and the hospital laboratory. Eur J Emerg Med. 2014; 21:310–313
50. Dashevsky M, Bernstein SL, Barsky CL, Taylor RA. Agreement between serum assays performed in ED point-of-care and hospital central laboratories. West J Emerg Med. 2017; 18:403–409
51. Alfonzo A, Soar J, MacTier R. Clinical practice guidelines: treatment of acute hyperkalemia
in adults. UK Renal Association. 2014
52. Mitra JK, Pandia MP, Dash HH, Tomar AK. Moderate hyperkalaemia without ECG changes in the intraoperative period. Acta Anaesthesiol Scand. 2008; 52:444–445
53. Ryuge A, Nomura A, Shimizu H, Fujita Y. Warning: the ECG may be normal in severe hyperkalemia
. Intern Med. 2017; 56:2243–2244
54. Szerlip HM, Weiss J, Singer I. Profound hyperkalemia
without electrocardiographic manifestations. Am J Kidney Dis. 1986; 7:461–465
55. Moulik PK, Nethaji C, Khaleeli AA. Misleading electrocardiographic results in patient with hyperkalaemia and diabetic ketoacidosis. BMJ. 2002; 325:1346–1347
56. Davey M, Caldicott D. Calcium salts in management of hyperkalaemia. Emerg Med J. 2002; 19:92–93
57. Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J. 1999; 75:554–556
58. Fenton F, Smally AJ, Laut J. Hyperkalemia
and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996; 28:440–441
59. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011; 40:41–46
60. Harel Z, Kamel KS. Optimal dose and method of administration of intravenous insulin in the management of emergency hyperkalemia
: a systematic review. PLoS One. 2016; 11:e0154963
61. LaRue HA, Peksa GD, Shah SC. A comparison of insulin doses for the treatment of hyperkalemia
in patients with renal insufficiency. Pharmacotherapy. 2017; 37:1516–1522
62. McNicholas BA, Pham MH, Carli K, Chen CH, Colobong-Smith N, Anderson AE, Pham H. Treatment of hyperkalemia
with a low-dose insulin protocol is effective and results in reduced hypoglycemia. Kidney Int Rep. 2018; 3:328–336
63. Batterink J, Cessford TA, Taylor RAI. Pharmacological interventions for the acute
management of hyperkalaemia in adults. Cochrane Database Syst Rev. 2015 CD010344
64. Mahoney BA, Smith WA, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency
interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005 CD003235
65. Kim HJ. Acute
therapy for hyperkalemia
with the combined regimen of bicarbonate and beta(2)-adrenergic agonist (salbutamol) in chronic renal failure patients. J Korean Med Sci. 1997; 12:111–116
66. Kaplan JL, Braitman LE, Dalsey WC, Montgomery M, Mangione A. Alkalinization is ineffective for severe hyperkalemia
in nonnephrectomized dogs. Hyperkalemia
research group. Acad Emerg Med. 1997; 4:93–99
67. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don’t: potassium
binding resins in hyperkalemia
. Clin J Am Soc Nephrol. 2010; 5:1723–1726
68. Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2019; pii:gfz150
69. Noel JA, Bota SE, Petrcich W, Garg AX, Carrero JJ, Harel Z, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019; 179:1025–1033
70. Hoy SM. Sodium zirconium cyclosilicate: a review in hyperkalaemia. Drugs. 2018; 78:1605–1613
71. Rafique Z, Weir MR, Onuigbo M, Pitt B, Lafayette R, Butler J, et al. Expert panel recommendations for the identification and management of hyperkalemia
and role of patiromer in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm. 2017; 23:S10–S19
72. Kosiborod M, Peacock WF, Packham DK. Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia
. N Engl J Med. 2015; 372:1577–1578
73. Packham DK, Kosiborod M. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia
. Expert Opin Drug Metab Toxicol. 2016; 12:567–573
74. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al. Sodium zirconium cyclosilicate in hyperkalemia
. N Engl J Med. 2015; 372:222–231
75. Amin AN, Menoyo J, Singh B, Kim CS. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium
level ≥5.5 mmol/L: pooled analysis from two phase 3 trials. BMC Nephrol. 2019; 20:440
76. Rafique Z, Liu M, Staggers KA, Minard CG, Peacock WF. Patiromer for treatment of hyperkalemia
in the emergency
department: a pilot study. Acad Emerg Med. 2020; 27:54–60
77. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia
in hemodialysis patients. Kidney Int. 1990; 38:869–872
78. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia
in patients on hemodialysis. Ann Intern Med. 1989; 110:426–429
79. Singer AJ, Thode HC Jr, Peacock WF. Rapid correction of hyperkalemia
is associated with reduced mortality in ED patients. Am J Emerg Med. 2019; pii:S0735–6757(19)30803-4
80. Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia
. CMAJ. 2010; 182:1631–1635
81. Kessler C, Ng J, Valdez K, Xie H, Geiger B. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia
. J Hosp Med. 2011; 6:136–140
82. Campese VM, Adenuga G. Electrophysiological and clinical consequences of hyperkalemia
. Kidney Int Suppl (2011). 2016; 6:16–19